Cited by 149Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes Management and Education

The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.

Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes

Open access
Umpierrez, Guillermo E., P. Kovatchev, Boris·2018·The American Journal of the Medical Sciences

Abstract

(A1C) levels have traditionally been the gold standard for assessing glycemic control and treatment efficacy in patients with type 2 diabetes. However, A1C does not take into account fluctuations in blood glucose levels known as glycemic variability (GV). In recent years, GV has become increasingly clinically relevant, because of a better understanding of the need to reach target A1C while avoiding hypoglycemia. GV relates to both hyperglycemia and hypoglycemia, and has been associated with poorer quality of life. Diabetes treatments targeting multiple pathophysiological mechanisms are most beneficial in controlling A1C and reducing GV. In clinical trials, a number of metrics are used to measure GV, many of which are not well understood in the clinical practice. Until a gold standard metric for GV is established, the variety of measurements available may confound the choice of an optimal treatment for an individual patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.amjms.2018.09.010

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 67 references

1 of the 67 references couldn’t be matched to a known paper.

Research works printed but not linked: 15

  1. de Ranitz-Greven, 2015, Is higher glycemic variability in type 2 diabetes patients associated with reduced quality of life?, Endocr Rev, 36, 2015
  2. Inzucchi, 2012, Association of measures of glycemic variability with glycemic control and hypoglycemic events, Diabetes, 61, A291
  3. Jangam, 2016, Reduction in glycemic variability is correlated with reductions in both hypoglycemia and hyperglycemia risk in type 1 and type 2 subjects, Diabetes Technol Ther, 18, A42
  4. Bailey, 2017, Within-day variability based on 9-point profiles correlates with risk of overall and nocturnal hypoglycemia in adults with type 1 (T1D) and type 2 diabetes (T2D), Diabetes, 66, A107
  5. McMahon, 2016, Glycometrics in 70,167 patients with type 2 diabetes derived from retrospective continuous glucose monitoring (CGM), Diabetes Technol Ther, 18, A28
  6. Noyes, 2016, Characteristics of patients with low and high HbA(1c) variability in type 2 diabetes, Diabetologia, 59, S61
  7. Beliaeva, 2013, The impact of glycemic variability on local contractility of the left ventricular in acute period of myocardial infarction, Cardiology (Switzerland), 126, 93
  8. Lowe, 2012, Glucose variability as a predictor of poor clinical outcomes among hospital in patients with diabetes mellitus, J Diabetes Sci Technol, 6, A16
  9. Pozzilli, 2016, CSII and other technologies for preventing beta cell failure in type 2 diabetes, Diabetes Technol Ther, 18, A1
  10. Kovatchev, 2017, The association between iglarlixi and patient satisfaction with their treatment's ability to control type 2 diabetes (T2D) is mediated by reduced glycemic variability (GV), Diabetes, 66, A624
  11. Yusoff, 2017, Glycaemic variability with dapagliflozin compared to saxagliptin in type 2 diabetic patients during Ramadan fasting, Endocr Rev, 38
  12. Vilsboll, 2015, Assessment of glycaemic control by continuous glucose monitoring in patients with type 2 diabetes treated with IDegLira, Diabetologia, 58, S401
  13. Bajaj, 2014, Least glucose variability is observed with the combination of a GLP-1 receptor agonist and basal insulin among four commonly used insulin regimens in type 2 diabetes, Can J Diabetes, 38, S41
  14. Sainsbury, 2016, Sulphonylurea use is positively and metformin inversely associated with an increased rate of hypoglycaemia, glucose variability and 5 year mortality amongst inpatients with Type 2 diabetes in a retrospective matched cohort study, Diabet Med, 33, 193
  15. Caffrey M. Abbott's Freestyle Libre CGM Gains Medicare Coverage. American Journal of Managed Care Website. https://www.ajmc.com/newsroom/abbotts-freestyle-libre-cgm-gains-medicare-coverage. Published January 5, 2018. Accessed July 11, 2018.

Cited by

Sorted by citations

Items 101–149 of 149

Metadata

Authors
Umpierrez, G. E., & P. Kovatchev, B.
Affiliations
Emory University (US)
Corresponding author
Umpierrez, Guillermo E.
Venue
The American Journal of the Medical Sciences
Publisher
Elsevier BV
Published
2018-12
Volume
356
Issue
6
Pages
518-527
ISSN
0002-9629 (ISSN-L)
OpenAlex
W2895746197
Cited by
148
References
67
Citations by year
2026: 10 · 2025: 12 · 2024: 23 · 2023: 25 · 2022: 31 · 2021: 27 · 2020: 13 · 2019: 7
FWCI
1.88
Type
journal article
Language
en
Open access
Locations
  • The American Journal of the Medical Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • University of Virginia
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Merck
  • National Center for Research Resources
  • Sanofi
  • Boehringer Ingelheim
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
glycemic variability, type 2 diabetes, HbA1c, glycemic control, hypoglycemia, hyperglycemia, quality of life
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review